ArticleHematology, transfusion and cell therapy2024

Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method.

Astrid Pavlovsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.